← Back to all trials
Recruiting
NCT06668181
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Conditions: Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis
Sex: All
Ages: 2 Years – 18 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 40
Sponsor: UCB Biopharma SRL
Location: Ja0005 50646 Calgary
Summary
The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.
Eligibility Criteria
Inclusion Criteria:
* Study participant must be 2 to \
Source: ClinicalTrials.gov (NCT06668181). StuddyBuddy aggregates publicly available trial information.
